The Immunoscore in Localized Urothelial Carcinoma Treated with Neoadjuvant Chemotherapy: Clinical Significance for Pathologic Responses and Overall Survival.
Immunoscore
immuno-oncology
neoadjuvant chemotherapy
predictive response to chemotherapy
prognostic score
urothelial carcinoma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
28 Jan 2021
28 Jan 2021
Historique:
received:
05
01
2021
revised:
21
01
2021
accepted:
22
01
2021
entrez:
2
2
2021
pubmed:
3
2
2021
medline:
3
2
2021
Statut:
epublish
Résumé
(1) Background-The five-year overall survival (OS) of muscle-invasive bladder cancer (MIBC) with neoadjuvant chemotherapy and cystectomy is around 50%. There is no validated biomarker to guide the treatment decision. We investigated whether the Immunoscore (IS) could predict the pathologic response to neoadjuvant chemotherapy and survival outcomes. (2) Methods-This retrospective study evaluated the IS in 117 patients treated using neoadjuvant chemotherapy for localized MIBC from six centers (France and Greece). Pre-treatment tumor samples were immunostained for CD3+ and CD8+ T cells and quantified to determine the IS. The results were associated with the response to neoadjuvant chemotherapy, time to recurrence (TTR), and OS. (3) Results-Low (IS-0), intermediate (IS-1-2), and high (IS-3-4) ISs were observed in 36.5, 43.7, and 19.8% of the cohort, respectively. IS was positively associated with a pathologic complete response (pCR;
Identifiants
pubmed: 33525361
pii: cancers13030494
doi: 10.3390/cancers13030494
pmc: PMC7865364
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : FONCER
ID : 5
Références
Nature. 2007 Dec 6;450(7171):903-7
pubmed: 18026089
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29
pubmed: 25559415
Ann Oncol. 2014 Sep;25 Suppl 3:iii40-8
pubmed: 25096609
J Urol. 1999 Jan;161(1):72-6
pubmed: 10037372
Immunity. 2016 Mar 15;44(3):698-711
pubmed: 26982367
Eur Urol. 2020 Apr;77(4):439-446
pubmed: 31708296
Nat Rev Cancer. 2020 Nov;20(11):662-680
pubmed: 32753728
J Immunother Cancer. 2020 May;8(1):
pubmed: 32448798
Lancet. 2018 Feb 24;391(10122):748-757
pubmed: 29268948
Lancet. 2018 May 26;391(10135):2128-2139
pubmed: 29754777
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
Cancer Immunol Res. 2019 Jun;7(6):923-938
pubmed: 30988029
Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):3967-72
pubmed: 17360461
J Urol. 2003 Sep;170(3):964-9
pubmed: 12913751
Oncoimmunology. 2014 Jan 1;3(1):e27456
pubmed: 24800163
Lancet Oncol. 2017 Mar;18(3):312-322
pubmed: 28131785
Bull Cancer. 2020 Jun;107(5S):eS8-eS15
pubmed: 32620213
Semin Immunopathol. 2011 Jul;33(4):335-40
pubmed: 21461991
Nat Med. 2020 Dec;26(12):1845-1851
pubmed: 33046869
Cancer. 2009 Sep 15;115(18):4104-9
pubmed: 19517476
Eur Urol. 2019 Jul;76(1):59-68
pubmed: 30712971
J Clin Oncol. 2011 Feb 20;29(6):610-8
pubmed: 21245428
Ann Oncol. 2020 Jul;31(7):921-929
pubmed: 32294529
PLoS One. 2018 Oct 11;13(10):e0205746
pubmed: 30308033
J Pathol. 2014 Jan;232(2):199-209
pubmed: 24122236
Sci Rep. 2020 Jan 29;10(1):1439
pubmed: 31996725
Oncoimmunology. 2020 Oct 13;9(1):1826132
pubmed: 33194317
J Clin Oncol. 2020 Nov 1;38(31):3638-3651
pubmed: 32897827
Int J Mol Sci. 2020 Nov 09;21(21):
pubmed: 33182484
JAMA Oncol. 2017 Sep 14;3(9):e172411
pubmed: 28817753
N Engl J Med. 2017 Mar 16;376(11):1015-1026
pubmed: 28212060
Immunity. 2020 Jan 14;52(1):55-81
pubmed: 31940273
Lancet. 2020 May 16;395(10236):1547-1557
pubmed: 32416780
CA Cancer J Clin. 2017 Mar;67(2):93-99
pubmed: 28094848
J Transl Med. 2012 Jan 03;10:1
pubmed: 22214470
J Clin Oncol. 2017 Jul 1;35(19):2117-2124
pubmed: 28375787
JNCI Cancer Spectr. 2020 Apr 05;4(3):pkaa023
pubmed: 32455336
N Engl J Med. 2003 Aug 28;349(9):859-66
pubmed: 12944571
Eur Urol. 2005 Aug;48(2):202-5; discussion 205-6
pubmed: 15939524
Eur Urol. 2017 Mar;71(3):462-475
pubmed: 27375033
Urol Oncol. 2014 Aug;32(6):791-7
pubmed: 24794251